Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

However, analysts project potential upside of 92% in 2025, according to the Street-high estimate.  Investors should also note that Merck pays a dividend yielding 3.71%, more than twice the healthcare ...

Explore the evolution of vaccine technology from Jenner to mRNA, highlighting India's role in COVID-19 vaccine development.

Palantir shares surged over 20% in extended trading Monday after reporting fourth-quarter earnings and revenue that exceeded Wall Street estimates. The software company projected higher-than-expected ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to turn the call over to Mr. Peter ...

Also Read: RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing The sales range reflects a decision to temporarily pause Gardasil/Gardasil 9 shipments into China beginning ...

Arvinas announced that chief commercial officer John Northcott is leaving his post ... instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, according to ...

Gardasil has recently seen slumping sales in China, where it's being marketed by Merck’s regional commercial partner Zhifei Biological Products. Rob David previously called the expansion to the ...

In other poultry developments, APHIS confirmed the virus on a commercial turkey farm in California's San ... quadrivalent (four-strain [4vHPV]), which targets types 6/11/16/18 (Gardasil); and ...

The system will operate using commercial cloud platforms in compliance with industry ... Additionally, schoolgirls aged 9-14 will receive the HPV vaccine against cervical cancer as a primary ...

Pause on Gardasil China sales from Feb to at least mid-2025 Keytruda beats, Gardasil misses Q4 sales estimates Merck pulls Gardasil's long-term sales target Shares tumble 11% in early trading Feb ...